The 8$^{\text{th}}$ and 9$^{\text{th}}$ transmembrane domains in organic anion-transporting polypeptide (OATP) 1B1 affects the transport kinetics of estrone-3-sulfate and estradiol-17β-D-glucuronide

Mayuko Miyagawa, Kazuya Maeda, Akinori Aoyama and Yuichi Sugiyama

Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan (M.M., K.M., A.A., Y.S.)

1

Running title: Importance of 8th and 9th transmembrane domains in OATP1B1

Corresponding author: Yuichi Sugiyama, Ph. D.

Address: Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

Phone: +81-3-5841-4770

Fax: +81-3-5841-4766

E-mail: sugiyama@mol.f.u-tokyo.ac.jp

The number of text pages: 36

The number of figures: 7

The number of tables: 2

The number of references: 25

The number of words in Abstract: 244 words

The number of words in Introduction: 735 words

The number of words in Discussion: 1189 words

Abbreviations: OATP, organic anion-transporting polypeptide; SLC, solute carrier; DMEM, Dulbecco's modified Eagle's medium; E-sul, estrone-3-sulfate; EG, estradiol-17β-D-glucuronide; HEK, human embryonic kidney; TM, transmembrane domain; CCK-8, cholecystokinin octapeptide

Recommended section: Metabolism, Transport, and Pharmacogenomics

Abstract

OATP1B1 and OATP1B3 are responsible for the hepatic uptake of organic anions. They share similar sequences and structures with 12 putative transmembrane domains (TMs). Their substrate specificities are very broad and overlap each other, whereas each transporter specifically recognizes certain substrates. Because the homology of the amino acid sequence in the latter part of OATP1B1 and OATP1B3 is relatively low, to determine which TMs in the latter part of OATP1B1 are important for its substrate recognition, we constructed several cell lines expressing chimeric transporters in which some TMs of OATP1B1 were substituted with those of OATP1B3, and investigated the transport kinetics of estrone-3-sulfate (E-sul; a substrate preferentially accepted by OATP1B1) and estradiol-17β-D-glucuronide (EG; a substrate accepted by both transporters). As the number of substituted TMs at the N-terminus with those of OATP1B3 increased, the K_m value of E-sul greatly increased and its uptake clearance decreased. The substitution of TM7 or TM9 of OATP1B1 with that of OATP1B3 (named 1B1-TM7 or 1B1-TM9) did not change the transport kinetics of EG, whereas the K_m value of E-sul in 1B1-TM9 increased 7.4-fold. On the other hand, the substitution of TM8 resulted in an 18-fold increase in the K_m value of E-sul and abolished the transporter-mediated uptake of EG. These

results suggest that TM8 in OATP1B1 is critical for the substrate recognition of

both E-sul and EG, and that TM9 is important for the recognition of E-sul, while it

is interchangeable with that of OATP1B3 for EG transport.

Introduction

To protect the body from exposure to various endogenous and exogenous compounds, many kinds of transporters and metabolic enzymes are expressed and substrate specificity of each protein is generally very broad. However, the underlying mechanisms to explain why each drug transporter can accept a wide variety of compounds as substrates so far remain to be elucidated because the crystal structures of mammalian drug transporters have not yet been solved. Recently, some reports have created *in silico* models to explain the substrate specificity of drug transporters by using ligand-based drug design approach (Chang et al., 2005). However, there are few studies identifying the exact binding sites of multiple substrates in drug transporters from *in silico* analysis.

Organic anion-transporting polypeptide (OATP) 1B1 and OATP1B3 are predominantly expressed on the basolateral membrane of human hepatocytes (Abe et al., 1999; Hsiang et al., 1999; Konig et al., 2000b; Konig et al., 2000a; Abe et al., 2001). The genomic sequence of OATP1B1 and OATP1B3 is arranged in tandem on the same locus and their genomic exon–intron coordination is very similar (Konig et al., 2000a). The homology of their amino acid sequences is 80% and they share the same structure with 12 putative

transmembrane domains (TMs). The substrate specificity of OATP1B1 and

OATP1B3 is very broad and various structurally unrelated compounds can be

accepted by these transporters as substrates. Moreover, the substrate

specificity of OATP1B1 often overlaps with that of OATP1B3, such as that for

estradiol 17β-D-glucuronide (EG), taurocholate, thyroid hormones,

sulfobromophthalein, and clinically used drugs (including HMG-CoA reductase

inhibitors and angiotensin II receptor antagonists) (Tirona and Kim, 2007).

Several lines of clinical evidence have suggested that the change in the

transport function of OATP1B1 caused by genetic polymorphisms and drug–drug

interactions affects the pharmacokinetics and subsequent

pharmacological/toxicological effect of multiple anionic drugs (Shitara et al.,

2005; Maeda and Sugiyama, 2008). Hirano et al. have established several

methodologies for estimating the contribution of OATP1B1 and OATP1B3 to the

overall hepatic uptake of compounds (Hirano et al., 2004). These approaches

have revealed that HMG-CoA reductase inhibitors (pitavastatin, rosuvastatin) are

generally taken up into human hepatocytes predominantly via OATP1B1 (Hirano

et al., 2004; Kitamura et al., 2008), while angiotensin II receptor antagonists

(valsartan, olmesartan) are taken up via both OATP1B1 and OATP1B3 to the

same extent (Yamashiro et al., 2006; Yamada et al., 2007). Thus, OATP1B1 and

OATP1B3 are responsible for the hepatic uptake of organic anions in humans.

Though these transporters show overlapping substrate specificities, some

substrates are highly specific to each transporter. For example, E-sul,

caspofungin, and SN-38 (active metabolite of irinotecan) are reported to be

specifically transported by OATP1B1, but not OATP1B3 (Hirano et al., 2004;

Nozawa et al., 2005; Sandhu et al., 2005). On the other hand, cholecystokinin

octapeptide (CCK-8), telmisartan, and docetaxel are transported only by

OATP1B3 (Ismair et al., 2001; Smith et al., 2005; Ishiguro et al., 2006). This

suggests that even the substrate recognition properties of highly homologous

transporters, OATP1B1 and OATP1B3, are somewhat different, and may be the

result of small differences in their amino acid sequences.   To explore the amino

acids important for discriminating the substrate specificity of OATP1B1 and

OATP1B3, the creation of several chimeric proteins using parts of OATP1B1 and

OATP1B3 is a powerful approach for determining which TMs are

interchangeable and narrowing the candidate binding sites of transporter

substrates.   During the preparation of our paper, Gui et al. have shown that

three amino acids in TM10 of OATP1B3 are critical for the transport of CCK-8

using several kinds of chimeric proteins in which TMs of OATP1B3 are

substituted with those from OATP1B1 (Gui and Hagenbuch, 2008). However,

little is known about the molecular mechanism for the broad but strict substrate

specificity of OATP1B1, and the important binding sites for its substrates have

not been clarified. Especially in the latter part of OATP1B1 and OATP1B3

sequences, the homology of amino acid sequence is relatively lower, which

implies that this region might be important for substrate recognition by

OATP1B1.

Therefore, the purpose of this study was to clarify the difference and

similarity of the substrate recognition properties of OATP1B1 and OATP1B3.

To achieve this goal, we especially focused on the latter half of TMs and

observed the effect of the exchange of TMs in OATP1B1 with those of OATP1B3

on the transport properties of their common substrate, EG and the

OATP1B1-selective substrate, E-sul, by using a series of chimeric OATP1B1

transporters.

Methods

Materials. [^{3}H]-Estradiol-17β-D-glucuronide (EG) (45 μCi/nmol) and [^{3}H]-estrone-3-sulfate (E-sul) (46 μCi/nmol) were purchased from PerkinElmer Life & Analytical Sciences (Boston, MA). [^{3}H]-cholecystokinin octapeptide (CCK-8) (77 Ci/mmol) was purchased from GE Healthcare UK Limited (Little Chalfont, Buckinghamshire, UK). All other chemicals were commercially available and of reagent grade.

Definition of the names for chimeric OATP1B1 proteins. As shown in Fig. 1, a chimeric OATP1B1 protein, in which the 1st to N^{th} transmembrane domains (TMs) of OATP1B1 were substituted with those of OATP1B3, is named "1B1-TM1-N." A mutated protein, in which the Nth TM of OATP1B1 was replaced with that of OATP1B3, is named "1B1-TMN."

Construction of the plasmid vectors for chimeric proteins. Using previously-constructed pcDNA3.1(+)/Neo vectors carrying human OATP1B1 and OATP1B3 cDNA (Hirano et al., 2004) as templates, mammalian expression vectors for chimeric proteins including 1B1-TM1-3, 1B1-TM1-6, 1B1-TM1-7, 1B1-TM1-8, and 1B1-TM1-9 were amplified by overlap extension PCR. The pcDNA3.1(+)/Neo expression vectors for mutated proteins, whose single

9

transmembrane domain (TM) of OATP1B1 was substituted with that from

OATP1B3 including 1B1-TM8, 1B1-TM8, and 1B1-TM9, were constructed using

a QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) as

previously described (Geiser et al., 2001). The sequences of all the constructs

were verified using a DNA sequencer (3130xl Genetic Analyzers, Applied

Biosystems, Foster City, CA).

Cell culture and transfection of plasmid vectors into cells. Each

pcDNA3.1(+)/Neo expression vector carrying cDNA of chimeric transporter was

transfected into HEK293 cells using FuGENE6 reagent (Roche Diagnostics,

Indianapolis, IN) as described previously (Hirano et al., 2004). The transfected

HEK293 cells were selected with G418 (800 μg/ml; Invitrogen). HEK293 cells

stably expressing each type of chimeric transporter were cultured in low-glucose

Dulbecco's modified Eagle's medium (DMEM; GIBCO BRL, Gaithersburg, MD,

USA) with 10% fetal bovine serum (Sigma, St. Louis, MO) and 1%

antibiotic-antimycotic solution (GIBCO) at 37 °C under 5% CO_2 and 95%

humidity.

Western blot analysis. Crude membrane was prepared from HEK293 cells as

previously reported (Sasaki et al., 2002). After the crude membrane fraction was

suspended in PBS, it was immediately frozen in liquid N_2 and stored at $-80\ ^\circ$C

until used. The protein concentration of the crude membrane fractions

prepared from HEK293 cells was determined by the method of Lowry with

bovine serum albumin as a standard. The membrane fraction was dissolved in

$3 \times$ SDS sample buffer (New England BioLabs, Beverly, MA) and loaded onto a

7% SDS-polyacrylamide electrophoresis gel with a 3.75% stacking gel. The

molecular weight was determined using a prestained protein marker (New

England BioLabs, Beverly, MA). Proteins were transferred electrophoretically

to a polyvinylidene difluoride membrane (Pall, East Hills, NY) using a blotter

(Trans-blot; Bio-Rad Laboratories, Hercules, CA) at 15 V for 1 h. The

membrane was blocked with Tris-buffered saline containing 0.05% Tween 20

(TTBS) and 5% skimmed milk for 1 h at room temperature. After washing with

TTBS, the membrane was incubated overnight at 4 $^\circ$C in TTBS with 500-fold

diluted anti-OATP1B1 antiserum that we had previously produced in rabbit

(Hirano et al., 2004). For the detection of each transporter, the membrane was

placed in contact with 5000-fold diluted donkey anti-rabbit IgG conjugated with

the horseradish peroxidase (Amersham Biosciences, Dedham, MA) for 1 h in

TTBS. The immunoreactive band was detected using an ECL Plus Western

blotting Starter Kit (Amersham Biosciences) and its intensity was quantified using a luminescent image analyzer (LAS-3000 mini; Fuji Film, Tokyo, Japan).

Immunocytochemical staining. HEK293 cells stably expressing chimeric, and single TM-substituted OATP1B1 proteins were grown on a poly-L-lysine-coated cover glass (Micro cover glass, 18 × 18 mm and 0.12–0.17 mm thick, Matsunami Glass, Osaka, Japan). After fixation at –20 °C with methanol for 10 min and permeabilization with 1% Triton-X100 containing PBS for 5 min, cells were incubated with rabbit antiserum raised against the carboxyl terminus of human OATP1B1 diluted 50-fold in PBS overnight at 4 °C, washed three times with PBS, and then incubated for 1 h at room temperature with goat anti-rabbit IgG Alexa 568 (Molecular Probes, Eugene, OR) diluted 250-fold in PBS in Fig. 3 or goat anti-rabbit IgG Alexa 488 (Molecular Probes) diluted 250-fold in PBS in Fig. 6 for 1 h. Nuclei were stained with 200-fold diluted TO-PRO-3 iodide (Molecular Probes). The localization was visualized using confocal laser microscopy (Zeiss LSM-510; Carl Zeiss, Thornwood, NY).

Transport study. The transport study was performed as reported previously (Hirano et al., 2004). Briefly, HEK293 cells were grown for 3 d in 12-well plates coated with poly-L-lysine and poly-L-ornithine (Sigma) and the normal culture

medium was replaced with the culture medium supplemented with 5 mM sodium

butyrate 24 h before the transport study to induce the expression of exogenous

transporters.   Uptake was initiated by adding Krebs–Henseleit buffer containing

radiolabeled and unlabeled substrates after cells were washed once and

preincubated with Krebs–Henseleit buffer at 37 °C for 15 min.   The

Krebs–Henseleit buffer consisted of 118 mM NaCl, 23.8 mM NaHCO$_3$, 4.83 mM

KCl, 0.96 mM KH$_2$PO$_4$, 1.20 mM MgSO$_4$, 12.5 mM HEPES, 5.0 mM glucose, and

1.53 mM CaCl$_2$ adjusted to pH 7.4.   The uptake was terminated at a designated

time by adding ice-cold Krebs–Henseleit buffer after removal of the incubation

buffer.   Then, cells were washed three times with 1 ml of ice-cold

Krebs–Henseleit buffer, solubilized in 500 µl of 0.2 N NaOH, and kept overnight

at room temperature, and then 250 µl of 0.4 N HCl was added.   The

radioactivity of cell lysate (500 µl) and incubation buffer (100 µl) was measured

in a liquid scintillation counter (QuantaSmart, PerkinElmer, Downers Grove, IL)

after mixing each sample with 3 ml of scintillation fluid (Clear-sol I; Nacalai

Tesque, Kyoto, Japan) in a scintillation vial.   The remaining 20 µl of cell lysate

was used to determine the protein concentration by the method of Lowry with

bovine serum albumin as a standard.

Kinetic analyses of the transport of substrates. Kinetic analysis was conducted as described previously (Hirano et al., 2004). Ligand uptake was expressed as the uptake volume (µl/mg of protein), given as the amount of radioactivity associated with the cells (dpm/mg of protein) divided by its concentration in the incubation medium (dpm/µl). Specific uptake was obtained by subtracting the uptake into vector-transfected cells from that into cDNA-transfected cells. Kinetic parameters were obtained using the following equations.

$$v = \frac{V_{max} \times S}{K_m + S},$$ (Eq. 1)

where v is the uptake velocity of the substrate (pmol/min/mg of protein), S is the substrate concentration in the medium (µM), K_m is the Michaelis–Menten constant (µM), and V_{max} is the maximum uptake rate (pmol/min/mg of protein). After v was normalized by the relative expression level of each chimeric protein to that of wild-type OATP1B1 by quantifying the band density of Western blots using a luminescent image analyzer (LAS-3000mini; Fuji Film), fitting was performed with the nonlinear least-squares method using MULTI software (Yamaoka et al., 1981) with the damping Gauss–Newton algorithm method.

Results

The expression and cellular localization of chimeric OATP1B1 proteins (1B1-TM1-3, 1B1-TM1-6, 1B1-TM1-7, 1B1-TM1-8, and 1B1-TM1-9)

To estimate the normalized V_{max} value of the uptake clearance of EG and E-sul in HEK293 cells expressing each chimeric OATP1B1 protein by the relative protein expression level, Western blot analysis was performed using the crude membrane fraction obtained from HEK293 cells expressing each chimeric protein and the band density of each chimeric protein was compared with that of wild-type OATP1B1 (Fig. 2). The specific band corresponding to each chimeric protein was observed at about 70–80 kDa (Fig. 2(A)), as shown previously (Iwai et al., 2004). The band density of wild-type OATP1B1 was proportional to the protein amount of the loaded sample within the range of 10–40 μg of protein/lane (Fig. 2(B)). Using the graph in Fig. 2(B) as a calibration curve, the ratio of the expression level of each chimeric protein to that of wild-type OATP1B1 was estimated (Fig. 2(C)).

Furthermore, the cellular localization of each chimeric OATP1B1 protein was investigated by immunocytochemical staining (Fig. 3). All of the chimeric OATP1B1 proteins (1B1-TM1-3, 1B1-TM1-6, 1B1-TM1-7, 1B1-TM1-8, and

1B1-TM1-9) as well as wild-type OATP1B1 were predominantly localized on the cell surface of HEK293 cells. No signal was observed in vector-transfected HEK293 cells.

The kinetic properties of the uptake of EG and E-sul in chimeric OATP1B1 proteins (1B1-TM1-3, 1B1-TM1-6, 1B1-TM1-7, 1B1-TM1-8, and 1B1-TM1-9)

Transport kinetics of EG and E-sul in each chimeric and wild-type protein can be explained by the one-saturable component (Fig. 4, Table 1). In the case of 1B1-TM1-9, the uptake clearance of EG and E-sul was not large enough to estimate the reliable kinetic parameters (EG: 2.9 ± 1.1 μL/min/mg protein, E-sul: 4.4 ± 0.2 μL/min/mg protein). The K_m value of E-sul in each chimeric OATP1B1 protein was greatly increased and its uptake clearance was decreased, as the number of substituted TMs with those of OATP1B3 was increased (Fig. 4(A)). On the other hand, the uptake clearance of EG was decreased mainly as a result of the decrease in V_{max} value, as the number of substituted TMs with those of OATP1B3 was increased, while the substitution of TM1-8 caused the slight increase in the K_m of EG (Fig. 4(B)).

16

The expression and cellular localization of single TM-substituted OATP1B1 proteins (1B1-TM7, 1B1-TM8, and 1B1-TM9)

To estimate the normalized V_{max} value of the uptake clearance of EG and E-sul in HEK293 cells expressing each chimeric OATP1B1 protein by the relative protein expression level, we used the same method as described above (Fig. 5). The specific band corresponding to each chimeric protein was observed at about 70–80 kDa (Fig. 5(A)), as shown previously (Iwai et al., 2004). The band density of wild-type OATP1B1 was proportional to the protein amount of the loaded sample within the range of 10–60 μg of protein/lane (Fig. 5(B)). Using the graph in Fig. 5(B) as a calibration curve, the ratio of the expression level of each chimeric protein to that of wild-type OATP1B1 was estimated (Fig. 5(C)).

Furthermore, the cellular localization of each single TM-substituted OATP1B1 protein was investigated by immunocytochemical staining (Fig. 6). 1B1-TM7, 1B1-TM8, and 1B1-TM9 as well as wild-type OATP1B1 were predominantly localized on the cell surface of HEK293 cells. No signal was observed in vector-transfected HEK293 cells.

The kinetic properties of the uptake of EG and E-sul in single

TM-substituted OATP1B1 proteins (1B1-TM7, 1B1-TM8, and 1B1-TM9)

Transport kinetics of EG and E-sul in each chimeric and wild-type protein can be explained by the one-saturable component judging from Eadie–Hofstee plots (Fig. 7, Table 2). In the case of 1B1-TM8, we could not observe any significant specific uptake of EG compared with the vector-control HEK293 cells. The substitution of TM7 with that of OATP1B3 did not greatly affect the transport kinetics of both E-sul and EG. However, the transport activity of E-sul and EG was drastically decreased in 1B1-TM8 and the K_m value for the transport of E-sul was increased 18-fold. Moreover, interestingly, the substitution of TM9 resulted in a 7.4-fold increase in the K_m value of E-sul, while that for EG was not significantly changed.

Discussion

In the present study, we constructed HEK293 cell lines expressing several kinds of chimeric OATP1B1 transporters and observed the transport kinetics of E-sul and EG to determine which TMs are important for substrate recognition by OATP1B1.

We first constructed a set of chimeric transporters in which TMs at the N-terminus originated from OATP1B3 and those at C-terminus from OATP1B1 and investigated the transport kinetics of EG (a substrate common to OATP1B1 and OATP1B3) and E-sul (a substrate preferentially accepted by OATP1B1). All of the chimeric OATP1B1 proteins were confirmed to be expressed in HEK293 cells by Western blot analysis and immunocytochemical staining. In Fig. 2(A), the apparent molecular mass of chimeric OATP1B1 proteins was significantly larger compared with wild-type OATP1B1. Our previous results indicated that the apparent molecular mass of OATP1B3 judged from Western blot analysis was significantly larger than that of OATP1B1 in our HEK293-based expression system (Hirano et al., 2004). Because chimeric OATP1B1 proteins have an N-terminal region identical to that of OATP1B3 and putative binding sites of N-glycosylation in OATP1B3 can be found in the second outer loop, chimeric

This article has not been copyedited and formatted. The final version may differ from this version.

OATP1B1 proteins may be highly glycosylated and their apparent molecular mass may be larger compared with wild-type OATP1B1.

By immunocytochemical staining, all of the chimeric proteins were found to be mainly localized on the cell surface as with wild-type OATP1B1 (Fig. 3), suggesting that substitution of TMs in OATP1B1 does not affect the correct sorting of OATP1B1 protein. Because both OATP1B1 and OATP1B3 are originally expressed on the membrane surface of HEK293 cells, they may both have the important amino acids for correct membrane sorting and substitution of TMs between OATP1B1 and OATP1B3 does not change the cellular localization of chimeric proteins.

As the result of uptake study, the K_m value of E-sul in 1B1-TM1-3 was not changed compared with wild-type OATP1B1, suggesting that the binding site of E-sul may not be located at TM1-3 of OATP1B1. On the other hand, substitution of TM1-6 of OATP1B1 with that of OATP1B3 resulted in the increase in its K_m value and as the number of the substituted TM increased, the K_m value of chimeric protein gradually increased, and it is 27-fold larger in 1B1-TM1-8 compared with wild-type OATP1B1. Moreover, substitution of TM1-9 resulted in the marked decrease in the transport activity of E-sul. It is possible that the

affinity of OATP1B1 for E-sul was further decreased by the substitution of TM1-9,

though we cannot estimate its K_m. These results suggest that the latter half of

OATP1B1 as well as TM4-6 may be important for the specific substrate

recognition of E-sul by OATP1B1. In the case of EG, its K_m value was not

largely changed by the substitution of TMs, though it was 2.3-fold higher in

1B1-TM1-8 than in wild-type OATP1B1. On the other hand, the V_{max} value

gradually decreased as the number of substituted TMs increased, suggesting

that the translocation efficiency of EG by chimeric transporter may be decreased.

In contrast, the binding site of EG was interchangeable between OATP1B1 and

OATP1B3, though the binding affinity of EG to OATP1B3 (24.6 μM (Hirano et al.,

2004)) was lower than that to OATP1B1.

Next, we focused on the latter part of OATP1B1 by searching the specific

recognition sites of E-sul in OATP1B1 using single TM-substituted chimeric

proteins because the homology of amino acid sequence in the latter part of TMs

is relatively low compared with that in the earlier part of the sequence.

Immunocytochemical staining revealed that all of the single TM-substituted

OATP1B1 proteins are mainly localized on the cell surface as with wild-type

OATP1B1 (Fig. 6), also suggesting that substitution of single TM in OATP1B1

does not affect the correct sorting of OATP1B1 protein.

Substitution of TM7 in OATP1B1 with that from OATP1B3 did not change any kinetic parameters of E-sul and EG, suggesting that TM7 is interchangeable between OATP1B1 and OATP1B3. A previous report indicated that a I353T mutation in TM7 resulted in a decrease in the transport activity of E-sul and EG (Tirona et al., 2001). In our study, isoleucine is located at position 353 of TM7 of both OATP1B1 and OATP1B3, and our finding is thought to be reasonable. A recent report indicated that substitution of TM7 in OATP1B3 with that from OATP1B1 also did not decrease the transport of the OATP1B3-specific substrate, CCK-8 (Gui and Hagenbuch, 2008). Therefore, it is suggested that TM7 does not determine the binding of transporter-specific substrates like E-sul by OATP1B1 or CCK-8 by OATP1B3.

On the contrary, the substitution of TM8 significantly increased by 18-fold the K_m value of E-sul compared with wild-type OATP1B1 and abolished the transport activity for EG. Because the transport activity for EG was about 8% of that for E-sul in wild-type OATP1B1, it might be possible that an increase in the K_m value to the same extent of E-sul results in the undetectable uptake of EG by 1B1-TM8. Therefore, TM8 is critical for EG and E-sul substrate recognition by

OATP1B1 and it is not interchangeable with that of OATP1B3. Tamai et al.

(2001) showed that the saturable transport of E-sul by OATP1B1 consists of two

saturable components, though we could not find its biphasic saturation in our

experiments. Tamai et al. (2001) reported that only the high-affinity site of E-sul

transport is inhibited by EG, while its low-affinity site is not inhibited by EG.   It

may be possible that TM8 in OATP1B1 works as a high-affinity binding site for

E-sul. A previous report indicated that substitution of TM8 in OATP1B3 with that

from OATP1B1 resulted in a partial decrease in the transport of CCK-8 (Gui and

Hagenbuch, 2008). These results suggest that TM8 may partially determine the

difference in the substrate specificity between OATP1B1 and OATP1B3.

Interestingly, the K_m value of E-sul was 7.4-fold higher in 1B1-TM9 than in

wild-type OATP1B1, while that of EG was not significantly changed. Thus, it is

suggested that TM9 as well as TM8 plays an important role in the substrate

recognition of E-sul by OATP1B1.   Regarding the EG transport, it is possible

that TM9 is not important for the substrate recognition of EG or that it has a

binding site for EG, which can be interchangeable between OATP1B1 and

OATP1B3. We cannot discriminate between these two possibilities at this time.

When comparing the amino acid sequence of TM8 and TM9 between

OATP1B1 and OATP1B3, 6 and 11 of 21 amino acids are different, respectively.

Some of these amino acids are considered to determine the substrate

recognition of EG and E-sul by OATP1B1. The transport kinetics of EG and E-sul

will be required to be observed using mutated proteins, whose single amino acid

in TM8 or TM9 is replaced with the other, to show the important binding sites for

EG and E-sul in OATP1B1.

In conclusion, we found that TM8 in OATP1B1 is critical for the transport of

E-sul and EG, whereas TM9 in OATP1B1 is also important for the transport of

E-sul. However, for EG it is interchangeable with that from OATP1B3. The

present data provide an insight into the structure–activity relationship of

OATP1B1 and help us to understand the very broad, yet specific substrate

specificity of OATP1B1.

References

Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki M, Naitoh T, Matsuno S and Yawo H (1999) Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. *J Biol Chem* **274**:17159-17163.

Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki T, Nunoki K, Sato E, Kakyo M, Nishio T, Sugita J, Asano N, Tanemoto M, Seki M, Date F, Ono K, Kondo Y, Shiiba K, Suzuki M, Ohtani H, Shimosegawa T, Iinuma K, Nagura H, Ito S and Matsuno S (2001) LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. *Gastroenterology* **120**:1689-1699.

Chang C, Ray A and Swaan P (2005) In silico strategies for modeling membrane transporter function. *Drug Discov Today* **10**:663-671.

Geiser M, Cebe R, Drewello D and Schmitz R (2001) Integration of PCR fragments at any specific site within cloning vectors without the use of restriction enzymes and DNA ligase. *Biotechniques* **31**:88-90, 92.

Gui C and Hagenbuch B (2008) Amino Acid Residues in Transmembrane

Domain 10 of Organic Anion Transporting Polypeptide 1B3 Are Critical for Cholecystokinin Octapeptide Transport. *Biochemistry*.

Hirano M, Maeda K, Shitara Y and Sugiyama Y (2004) Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. *J Pharmacol Exp Ther* **311**:139-146.

Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP and Kirchgessner TG (1999) A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. *J Biol Chem* **274**:37161-37168.

Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, Roth W, Igarashi T and Sugiyama Y (2006) Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. *Drug Metab Dispos* **34**:1109-1115.

Ismair MG, Stieger B, Cattori V, Hagenbuch B, Fried M, Meier PJ and Kullak-Ublick GA (2001) Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and

human liver. *Gastroenterology* **121**:1185-1190.

Iwai M, Suzuki H, Ieiri I, Otsubo K and Sugiyama Y (2004) Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). *Pharmacogenetics* **14**:749-757.

Kitamura S, Maeda K, Wang Y and Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. *Drug Metab Dispos.*

Konig J, Cui Y, Nies AT and Keppler D (2000a) Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. *J Biol Chem* **275**:23161-23168.

Konig J, Cui Y, Nies AT and Keppler D (2000b) A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. *Am J Physiol Gastrointest Liver Physiol* **278**:G156-164.

Maeda K and Sugiyama Y (2008) Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. *Drug Metab Pharmacokinet* **23**:223-235.

Nozawa T, Minami H, Sugiura S, Tsuji A and Tamai I (2005) Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and

its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. *Drug Metab Dispos* **33**:434-439.

Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG and Kim RB (2005) Hepatic uptake of the novel antifungal agent caspofungin. *Drug Metab Dispos* **33**:676-682.

Sasaki M, Suzuki H, Ito K, Abe T and Sugiyama Y (2002) Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). *J Biol Chem* **277**:6497-6503.

Shitara Y, Sato H and Sugiyama Y (2005) Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. *Annu Rev Pharmacol Toxicol* **45**:689-723.

Smith NF, Acharya MR, Desai N, Figg WD and Sparreboom A (2005) Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. *Cancer Biol Ther* **4**:815-818.

Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y and Tsuji A (2001) Functional

characterization of human organic anion transporting polypeptide B

(OATP-B) in comparison with liver-specific OATP-C. *Pharm Res*

18:1262-1269.

Tirona RG and Kim RB (2007) Organic anion-transporting polypeptides, in *Drug*

Transporters (You G and Morris ME eds) pp 75-104, John Wiley & Sons,

Inc., Ner Jersey.

Tirona RG, Leake BF, Merino G and Kim RB (2001) Polymorphisms in OATP-C:

identification of multiple allelic variants associated with altered transport

activity among European- and African-Americans. *J Biol Chem*

276:35669-35675.

Yamada A, Maeda K, Kamiyama E, Sugiyama D, Kondo T, Shiroyanagi Y,

Nakazawa H, Okano T, Adachi M, Schuetz JD, Adachi Y, Hu Z, Kusuhara

H and Sugiyama Y (2007) Multiple human isoforms of drug transporters

contribute to the hepatic and renal transport of olmesartan, a selective

antagonist of the angiotensin II AT1-receptor. *Drug Metab Dispos*

35:2166-2176.

Yamaoka K, Tanigawara Y, Nakagawa T and Uno T (1981) A pharmacokinetic

analysis program (multi) for microcomputer. *J Pharmacobiodyn*

4:879-885.

Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z and Sugiyama Y (2006)

Involvement of transporters in the hepatic uptake and biliary excretion of

valsartan, a selective antagonist of the angiotensin II AT1-receptor, in

humans. *Drug Metab Dispos* **34**:1247-1254.

Footnotes

Legends for Figures

Figure 1.   Schematic diagram of the name and structure of chimeric proteins used in this study

Black and white boxes represent the TMs originating from OATP1B1 and OATP1B3, respectively.   (A) The chimeric OATP1B1 protein in which the former part of the consecutive TMs (1st to N^{th}) is replaced with that of OATP1B3 is named "1B1-TM1-N." (B) The chimeric OATP1B1 protein in which single N^{th} TM is replaced with that of OATP1B3 is named "1B1-TMN."

Figure 2.   Quantification of the relative protein expression level of each chimeric OATP1B1 protein in crude membrane fractions from HEK293 transfectant by Western blot analysis

Crude membrane fractions prepared from each HEK293 transfectant were separated by SDS-PAGE.   Wild-type OATP1B1 and various types of chimeric OATP1B1 proteins in HEK293 transfectants were detected using rabbit antiserum raised against the carboxyl terminus of human OATP1B1 (A).   The amount of protein applied in each lane is indicated below the blot.   The band density of wild-type OATP1B1 in various protein amounts of the loaded crude

32

membrane fraction was quantified and plotted in (B) as a standard curve.   Then,

the ratio of the relative expression level of each chimeric protein to that of

wild-type OATP1B1 was calculated using the standard curve (C).   Each bar

represents the mean value of two independent determinations.

Figure 3.   Immunolocalization of chimeric OATP1B1 proteins in HEK293 cells

Wild-type and chimeric OATP1B1 proteins (red fluorescence) and nuclei (blue

fluorescence) were stained using the rabbit antiserum raised against the

carboxyl terminus of OATP1B1 and TO-PRO-3 iodide, respectively.

Each figure represents the immunocytochemical staining of HEK293 cells

expressing OATP1B1 (B), 1B1-TM1-3 (C), 1B1-TM1-6 (D), 1B1-TM1-7 (E),

1B1-TM1-8 (F), 1B1-TM1-9 (G) as well as vector-transfected control cells (A),

respectively.

Figure 4.   Eadie–Hofstee plots for the transport of E-sul and EG by HEK293 cells expressing each chimeric OATP1B1 protein

The concentration dependence of E-sul (A) and EG (B) uptake is shown as

Eadie–Hofstee plots.   The uptake of E-sul (for 0.5 min) and EG (for 2 min) was

measured in various concentrations (0.03–100 μM) in each transfectant.   The

transport velocity of E-sul and EG was normalized by the expression level of

each chimeric OATP1B1 protein determined by Western blot analysis as shown

in Fig. 2.   Each point and bar represents the mean ± S.E. (n = 6–9).   Each line

represents the fitted curve calculated by nonlinear regression based on Eq. 1, as

described in the *Methods* section.

Figure 5.   Quantification of the relative protein expression level of each

single TM-substituted OATP1B1 protein in crude membrane fraction from

HEK293 transfectant by Western blot analysis

Crude membrane fraction prepared from each HEK293 transfectant was

separated by SDS-PAGE.   Wild-type OATP1B1 and various types of single

TM-substituted proteins in HEK293 transfectants were detected using rabbit

antiserum raised against the carboxyl terminus of human OATP1B1 (A).   The

amount of protein applied to each lane was indicated below the blot in each lane.

The band density of wild-type OATP1B1 in various protein amounts of the loaded

crude membrane fraction was quantified and plotted in (B) as a standard curve.

Then, the ratio of the relative expression level of each chimeric protein to that of

wild-type OATP1B1 was calculated using a standard curve (C). Each bar

represents the mean ± S.E. of three independent determinations.

Figure 6. Immunolocalization of single TM-substituted OATP1B1 proteins

in HEK293 cells

Wild-type and single TM-substituted OATP1B1 proteins (green fluorescence)

and nuclei (blue fluorescence) were stained using the rabbit antiserum raised

against the carboxyl terminus of OATP1B1 and TO-PRO-3 iodide, respectively.

Each figure represents the immunocytochemical staining of HEK293 cells

expressing OATP1B1 (B), 1B1-TM7 (C), 1B1-TM8 (D), 1B1-TM9 (E) as well as

vector-transfected control cells (A), respectively.

Figure 7. Eadie–Hofstee plots for the transport of E-sul and EG by

HEK293 cells expressing each single TM-substituted OATP1B1 protein

The concentration dependence of E-sul (A) and EG (B) uptake is shown as

Eadie–Hofstee plots. The uptake of E-sul (for 0.5 min) and EG (for 5 min) was

measured in various concentrations (0.03–100 µM) in each transfectant. The

transport velocity of E-sul and EG was normalized by the expression level of

each single TM-substituted OATP1B1 protein determined by Western blot

analysis as shown in Fig. 5.　Each point and bar represents the mean $\pm$ S.E. (n

= 6–9).　Each line represents the fitted curve calculated by nonlinear regression

based on Eq. 1, as described in the *Methods* section.

Table 1.   Kinetic parameters for the transport of E-sul and EG by HEK293 cells expressing each chimeric OATP1B1 protein.

Data shown in Fig. 4 were used to determine these parameters calculated using nonlinear regression analysis as described in the *Methods* section.   Each parameter represents the mean $\pm$ calculated S.D.

**p < 0.01, significantly different from native OATP1B1

(A)

Transporter	K_m (μM)	Corrected V_{max} (pmol/min/mg protein)	Corrected V_{max}/K_m (μl/min/mg protein)
OATP1B1	0.162 ± 0.015	34.2 ± 1.4	211 ± 21
1B1-TM1-3	0.112 ± 0.022	9.74 ± 0.75 **	86.7 ± 17.9 **
1B1-TM1-6	0.723 ± 0.130 **	29.8 ± 3.3	41.2 ± 8.8 **
1B1-TM1-7	1.34 ± 0.30 **	17.8 ± 2.8 **	13.3 ± 3.6 **
1B1-TM1-8	4.42 ± 0.74 **	40.2 ± 5.4	9.08 ± 1.95 **
1B1-TM1-9	Not significantly transported		

(B)

Transporter	K_m (μM)	Corrected V_{max} (pmol/min/mg protein)	Corrected V_{max}/K_m (μl/min/mg protein)
OATP1B1	5.76 ± 0.28	135 ± 5	23.5 ± 1.4
1B1-TM1-3	2.69 ± 0.09 **	70.7 ± 1.6 **	26.3 ± 1.0
1B1-TM1-6	7.17 ± 0.41 **	60.7 ± 2.7 **	8.47 ± 0.62 **
1B1-TM1-7	7.65 ± 0.86	31.9 ± 2.8 **	4.17 ± 0.60 **
1B1-TM1-8	13.1 ± 2.1 **	17.8 ± 2.4 **	1.37 ± 0.29 **
1B1-TM1-9	Not significantly transported		

Table 2. Kinetic parameters for the transport of E-sul and EG by HEK293 cells expressing each single TM-substituted OATP1B1 protein.

Data shown in Fig. 7 were used to determine these parameters calculated by nonlinear regression analysis as described in the *Methods* section. Each parameter represents the mean $\pm$ calculated S.D.

*$p < 0.05$, significantly different from native OATP1B1

**$p < 0.01$, significantly different from native OATP1B1

(A)

	K_m (μM)	Corrected V_{max} (pmol/min/mg protein)	Corrected V_{max}/K_m (μl/min/mg protein)
OATP1B1	0.246 ± 0.038	43.8 ± 3.3	178 ± 18
1B1-TM7	0.120 ± 0.044 *	33.2 ± 5.0	278 ± 75
1B1-TM8	4.35 ± 0.66 **	87.1 ± 10.7 **	20.0 ± 1.0 **
1B1-TM9	1.82 ± 0.37 **	119 ± 17 **	65.3 ± 5.9 **

(B)

	K_m (μM)	Corrected V_{max} (pmol/min/mg protein)	Corrected V_{max}/K_m (μl/min/mg protein)
OATP1B1	6.31 ± 0.44	88.6 ± 4.6	14.0 ± 0.4
1B1-TM7	5.02 ± 1.07	78.1 ± 9.8	15.6 ± 2.0
1B1-TM8	Not significantly transported		
1B1-TM9	8.11 ± 1.60	104 ± 16	12.9 ± 1.1

Figure 1

(A)

(B)

Figure 2

(A)

(B)

(C)

Figure 3

(A)

(B)

(C)

(D)

(E)

(F)

(G)

Figure 4

(A)

(B)

Figure 5

(A)

(B)

(C)

Figure 6

(A)

(B)

(C)

(D)

(E)

Figure 7

(A)

(B)